Ke Chuangwu, Ren Yanchen, Lv Lu, Hu Weidong, Zhou Wenhui
Department of Thoracic Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Hubei Cancer Clinical Study Center and Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Oncol Lett. 2017 Jun;13(6):4661-4668. doi: 10.3892/ol.2017.6088. Epub 2017 Apr 24.
Lung cancer is a major cause of morbidity and mortality worldwide, therefore identifying biomarkers for the early detection, grading or postoperative follow-up of lung cancer is of clinical significance. In the present study, expression of lung tissue (t)-CXCL16 and t-CXCR6 was examined in 58 patients with non-small cell lung cancer (NSCLC) using immunohistochemical staining, and serum (s)-CXCL16 levels were detected in 58 patients with NSCLC and in 32 normal volunteers using an ELISA. A follow-up was performed every 4 months between January 2014 and January 2015. Compared with the normal volunteers, the s-CXCL16 concentration in patients with NSCLC significantly increased (329.47±135.38 vs. 572.82±116.05 pg/ml, respectively; P<0.001). When grouped according to TNM stage, the expression of t-CXCL16 (60 vs. 85.71%; P=0.029), t-CXCR6 (53.33 vs. 78.57%; P=0.043) and s-CXCL16 (26.67 vs. 57.14%, P=0.019) in the stage I-II subgroup was significantly lower compared with that of the stage III-IV subgroup. The positive expression rate of t-CXCL16 (91.18%) and t-CXCR6 (79.41%) in the lymph node metastasis subgroup was significantly higher compared with that of the corresponding non-lymph node metastasis subgroup (50 and 45.83%, respectively; P<0.01). Additionally, the positive expression rate of t-CXCL16 in the smoking subgroup was 100%, which was significantly higher compared with that of the non-smoking subgroup (23.81%) (P<0.001). The follow-up and mortality rates were 100% (58/58) and 13.79% (8/58), respectively. Within the time period of the present study, the survival time was 4-18 months, and the mean survival time was 16.6 months. In conclusion, the expression of t-CXCL16 and t-CXCR6 is positively correlated with the TNM stage and lymph node metastasis in patients with NSCLC. Additionally, there was a significant increase in s-CXCL16 levels in patients with NSCLC, suggesting that CXCL16 could be used as a supplementary biomarker for the early detection of NSCLC.
肺癌是全球发病和死亡的主要原因，因此，识别用于肺癌早期检测、分级或术后随访的生物标志物具有临床意义。在本研究中，采用免疫组织化学染色法检测了58例非小细胞肺癌（NSCLC）患者肺组织中t-CXCL16和t-CXCR6的表达，并采用酶联免疫吸附测定法检测了58例NSCLC患者和32例正常志愿者血清中s-CXCL16的水平。在2014年1月至2015年1月期间，每4个月进行一次随访。与正常志愿者相比，NSCLC患者的s-CXCL16浓度显著升高（分别为329.47±135.38 vs. 572.82±116.05 pg/ml；P<0.001）。根据TNM分期分组时，I-II期亚组中t-CXCL16（60% vs. 85.71%；P=0.029）、t-CXCR6（53.33% vs. 78.57%；P=0.043）和s-CXCL16（26.67% vs. 57.14%，P=0.019）的表达明显低于III-IV期亚组。淋巴结转移亚组中t-CXCL16（91.18%）和t-CXCR6（79.41%）的阳性表达率明显高于相应的无淋巴结转移亚组（分别为50%和45.83%；P<0.01）。此外，吸烟亚组中t-CXCL16的阳性表达率为100%，明显高于非吸烟亚组（23.81%）（P<0.001）。随访率和死亡率分别为100%（58/58）和13.79%（8/58）。在本研究时间段内，生存时间为4至18个月，平均生存时间为16.6个月。总之，t-CXCL16和t-CXCR6的表达与NSCLC患者的TNM分期和淋巴结转移呈正相关。此外，NSCLC患者的s-CXCL16水平显著升高，提示CXCL16可作为NSCLC早期检测的补充生物标志物。
